期刊
BLOOD
卷 127, 期 21, 页码 2536-2545出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2016-01-678128
关键词
-
类别
资金
- National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases [F30DK 103359]
- NIH National Heart, Lung, and Blood Institute [HL032259, P01HL032262]
Despite nearly complete understanding of the genetics of the beta-hemoglobinopathies for several decades, definitive treatment options have lagged behind. Recent developments in technologies for facile manipulation of the genome (zinc finger nucleases, transcription activator-like effector nucleases, or clustered regularly interspaced short palindromic repeats-based nucleases) raise prospects for their clinical application. The use of genome-editing technologies in autologous CD34(+) hematopoietic stem and progenitor cells represents a promising therapeutic avenue for the beta-globin disorders. Genetic correction strategies relying on the homology-directed repair pathway may repair genetic defects, whereas genetic disruption strategies relying on the nonhomologous end joining pathway may induce compensatory fetal hemoglobin expression. Harnessing the power of genome editing may usher in a second-generation form of gene therapy for the b-globin disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据